Skip to main content
. 2018 Nov 11;2018:3936706. doi: 10.1155/2018/3936706

Table 2.

VAD-treated vs. T-VAD-treated MM patients.

Study Stage Patients Age (years) Comparison Trial conditions and units
I/II/III Control (M/F) Exp (M/F) Control/Exp Control Exp
Cong et al., 2012 [27] 4/12/30∗∗ 23 23 65/68 VAD T-VAD ELISA
VEGF (ng/L)
Yang et al., 2015 [29] 6/26/58∗∗ 43 (23/20) 47 (25/22) 67.4/66.9 VAD T-VAD ELISA
VEGF (pg/ml)
Long et al., 2015 [30] 0/19/71∗ 45 (26/19) 45 (27/18) 56.4/55.3 VAD T-VAD ELISA
VEGF (ng/L)
Yuan et al., 2004 [31] 10/31/12∗ 30 (18/12) 23 (15/8) 62/61 VAD T-VAD ELISA
VEGF (ng/L)
Liu et al., 2016 [32] 0/24/26∗ 25 (12/13) 25 (13/12) 67.1/67.1 VAD T-VAD ELISA
VEGF (pg/ml)
Tan et al.,
2008 [33]		 11/33/12∗ 28 (16/12) 28 (15/13) 62/61 VAD T-VAD ELISA
VEGF (ng/L)
Yang et al., 2005 [34] 0/ 8/76∆ 45 (31/14) 39 (29/10) 51.5/52.3 VAD T-VAD ELISA
VEGF (ng/L)
Dong, 2004 [28] 7/8/19# 6 6 31.3/49.8 VAD T-VAD ELISA
VEGF (ng/L)